MedCap AB (FRA:61MA) LT-Debt-to-Total-Asset: 0.15 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:61MA MedCap AB FRA:61MA
91 GF Score
Price €45.54
GF Value €50.10
Valuation Fairly Valued
View Full Analysis

What is MedCap AB LT-Debt-to-Total-Asset?

MedCap AB FRA:61MA -0.22% 91 LT-Debt-to-Total-Asset is 0.15 as of Mar. 2026. GuruFocus rates FRA:61MA with a GF Score™ of 91/100 and a GF Value™ of €50.10 (Fairly Valued).

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. MedCap AB's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.15.

MedCap AB's long-term debt to total assets ratio increased from Mar. 2025 (0.14) to Mar. 2026 (0.15). It may suggest that MedCap AB is progressively becoming more dependent on debt to grow their business.

MedCap AB  (FRA:61MA) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

MedCap AB LT-Debt-to-Total-Asset Related Terms

MedCap AB LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for MedCap AB's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MedCap AB LT-Debt-to-Total-Asset Chart

MedCap AB Annual Data
Trend Apr16 Apr17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 0.16 0.12 0.15 0.15

MedCap AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.13 0.17 0.15 0.15
FRA:61MA
91GF Score
MedCap AB FRA:61MA
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MedCap AB LT-Debt-to-Total-Asset Calculation

MedCap AB's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=34.983/239.471
=0.15

MedCap AB's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=36.235/250.396
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.15 mean?
MedCap AB (FRA:61MA) has a LT-Debt-to-Total-Asset of 0.15 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on MedCap AB and its competitors.
Is MedCap AB's LT-Debt-to-Total-Asset too high?
MedCap AB's current LT-Debt-to-Total-Asset is 0.15. Overall, MedCap AB has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does MedCap AB's LT-Debt-to-Total-Asset compare to ABT and SYK?
MedCap AB's LT-Debt-to-Total-Asset of 0.15 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?
A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on MedCap AB and its competitors. MedCap AB's current LT-Debt-to-Total-Asset is 0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedCap AB stock overvalued right now?
Based on GuruFocus' analysis, MedCap AB (FRA:61MA) is currently considered Fairly Valued. The stock's GF Value™ is €50.10, compared to a current price of €45.54 — trading 9.1% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.15. MedCap AB's overall GF Score™ is 91/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For MedCap AB (FRA:61MA), the current LT-Debt-to-Total-Asset is 0.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MedCap AB (FRA:61MA) Overvalued in 2026?

Based on GuruFocus' analysis, MedCap AB stock appears to be undervalued. The current stock price of €45.54 is trading 9.1% below its estimated GF Value™ of €50.10. GuruFocus considers MedCap AB to be Fairly Valued.

Key valuation signals for FRA:61MA:

  • LT-Debt-to-Total-Asset: 0.15
  • GF Value™: €50.10 vs. price of €45.54 (9.1% below fair value)
  • GF Score™: 91/100

No single metric tells the full story. See the FRA:61MA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MedCap AB Business Description

Address Sundbybergsvagen 1, Solna, SWE, 171 73
MedCap AB acquires and develops profitable, market-leading niche companies in the Nordic life science industry. It is diversified into two business areas namely Medical technology and Specialist medicines. Medical Technology mainly develops and sells various medical technology products and services. Its Specialist medicines develop and sell medicines within the regulatory classes of registered, extemporaneous and licensed medicines.
91GF Score

Get the complete analysis for FRA:61MA

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€45.54
Price
€50.10
GF Value